ReviewFrontiers in pharmacology2026
Integrative management of gastric cardia cancer and precancerous lesions: prospects and mechanistic rationale for Banxia Xiexin Tang.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cardia cancer is a biologically heterogeneous malignancy arising at the gastroesophageal junction that is, the upper opening of the stomach rather than the heart. It develops along an inflammation-metaplasia-dysplasia-carcinoma sequence and remains clinically challenging because early lesions are often occult and advanced disease is shaped by a treatment-resistant tumor microenvironment. A clinically useful review therefore needs to distinguish gastric cardia cancer from non-cardia gastric cancer and from esophageal adenocarcinoma, while also clarifying where current evidence is direct and where it is only extrapolated. Banxia Xiexin Tang (BXT) is a seven-botanical formula containing Pinellia ternata (Thunb.) Makino. [Araceae] (Pinelliae Rhizoma), Coptis chinensis Franch. [Ranunculaceae] (Coptidis Rhizoma), Scutellaria baicalensis Georgi [Lamiaceae] (Scutellariae Radix), Zingiber officinale Roscoe [Zingiberaceae] (Zingiberis Rhizoma Recens), Panax ginseng C.A.Mey. [Araliaceae] (Ginseng Radix et Rhizoma), Glycyrrhiza uralensis Fisch. ex DC. [Fabaceae] (Glycyrrhizae Radix et Rhizoma), and Ziziphus jujuba Mill. [Rhamnaceae] (Jujubae Fructus). Available preclinical and supportive-care studies suggest that Banxia Xiexin Tang or selected metabolites within the formula may modulate inflammatory signaling, oxidative stress, epithelial barrier injury, and treatment-related gastrointestinal toxicity. However, the current evidence base is uneven: much of it comes from gastritis, reflux injury, or non-cardia gastric disease models rather than directly from human gastric cardia cancer. This review critically synthesizes the available literature on integrative management of gastric cardia cancer and related precancerous lesions, with emphasis on what the current data do support, what they do not support, and what research gaps remain. The revision adds a transparent search strategy, clearer terminology, a more cautious interpretation of pharmacological claims, and an explicit discussion of limitations. Because the included studies were heterogeneous in design, population, intervention, and outcome reporting, the evidence is synthesized narratively rather than through quantitative meta-analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.